SCHEMBL16815503

SCHEMBL16815503

COC(OC)c1ccnc(-c2ccccn2)n1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.54
▸ KMT2A Q03164 5/20 0.54
▸ SMN1; SMN2 Q16637 6/20 0.49
▸ KDM4E B2RXH2 4/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ ALDH1A1 P00352 3/20 0.46
▸ TRPM8 Q7Z2W7 4/20 0.46
▸ L3MBTL1 Q9Y468 8/20 0.45
▸ LMNA P02545 3/20 0.45
▸ MITF O75030 1/20 0.45
▸ HTT P42858 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ GRM5 P41594 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ PPP1CA P62136 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31587883 0.77 SMN1; SMN2 (0.46) MAPTKMT2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL16815482 0.75 CYP1A2 (0.58) MAPTKMT2ASMN1; SMN2KDM4ETDP1
SCHEMBL16815687 0.75 MAPT (0.52) MAPTKMT2ASMN1; SMN2KDM4ETDP1
SCHEMBL20742372 0.75 KMT2A (0.49) MAPTKMT2ASMN1; SMN2KDM4ETDP1
SCHEMBL16815681 0.75 KMT2A (0.49) MAPTKMT2ASMN1; SMN2KDM4ETDP1
SCHEMBL28020326 0.75 GAA (0.57) MAPTKMT2ASMN1; SMN2KDM4ETDP1
SCHEMBL16815686 0.73 SMN1; SMN2 (0.62) MAPTKMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL5840879 0.73 SLC6A3 (0.48) KMT2ASMN1; SMN2KDM4EALDH1A1L3MBTL1
SCHEMBL776048 0.73 KDM4E (0.67) MAPTKMT2ASMN1; SMN2KDM4ETDP1
SCHEMBL16815718 0.72 SMN1; SMN2 (0.53) MAPTKMT2ASMN1; SMN2KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2019-07-04 — — US disclosed
US-10278972-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2019-05-07 — — US disclosed
US-20170216293-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2017-08-03 — — US disclosed
US-9670227-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2017-06-06 — — US disclosed
EP-2886545-B1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2016-06-29 — — EP disclosed
WO-2015097123-A1 NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2015-07-02 — — WO disclosed
US-20150175623-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2015-06-25 — — US disclosed
EP-2886545-A1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2015-06-24 — — EP disclosed
CN-104725397-A Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them SERVIER LAB 2015-06-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216293-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 MAPT 2702/4885KMT2A 3050/4885SMN1; SMN2 1945/4885
US-10278972-B2 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them TYMS, TYMP, TPX2 MAPT 2702/4885KMT2A 3050/4885SMN1; SMN2 1945/4885
US-20190201404-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 MAPT 2702/4885KMT2A 3050/4885SMN1; SMN2 1945/4885
US-20150175623-A1 THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM TYMS, TYMP, TPX2 MAPT 2702/4885KMT2A 3050/4885SMN1; SMN2 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback